About Dr. Mukul Arvind Gharote

Dr. Mukul is a Medical and Pediatric Oncologist & Hematologic Oncologist with over 10 years of experience in the field of medicine. He specializes in Oncology, Hematology and Pediatric Oncology and majorly offers cancer treatment and chemotherapy for Breast Cancer, Breast cysts, Cancer management, Costochondritis, Fibrocystic Breast disease and Radiation therapy. He is currently practicing at Mukta Cancer Clinic in Nashik, Maharashtra.

Dr. Mukul has published several papers in various journals such as Rituximab (Anti Cd20 Antibody) Based Therapy : A Holy Grail for Both Haematological and Non Haematological Disorders in VJIM (2015), Basosquamous Carcinoma in Xeroderma Pigmentosum - A Unusual Case Report in VJIM (2015), Sensitive allele specific oligonucleotide – polymerase chain reaction (aso-pcr) in detection of pre-existing mutations in imatinib resistant chronic myelogenous leukemia patient – a retrospective analysis in Journal of applied haematology (2015), Benefits of the early detection of M351T mutation, by allele-specific oligonucleotide polymerase chain reaction, in imatinib-resistant chronic myelogenous leukemia (CML) - A retrospective analysis in International Journal of Molecular and Immuno-oncology (2018), Is continuous infusion of high dose ifosfamide, a safe option? (Drug review) in International Journal of Molecular and Immuno-oncology, Role of Nasopharyngeal lactate dehydrogenase as a possible economical mass screening test for the detection and segregation of SARS-CoV-2 (COVID-19) cases in India in Indian J Med Sci (2020), and many more. He has been invited as Speaker at International Conference on Blood Cancer (Dubai, 2016) to talk on Allele specific oligonucleotide polymerase chain reaction (AS0-PCR) as method of detection of three BCR-ABL kinase domain mutation (T315I, M351T, F311L) in imatinib resistant CML – A retrospective study.

Dr. Mukul continues to add value to the field of medicine as a practicing oncologist and is also a member of various professional bodies such as European Association of Cancer Research, American society of clinical oncology (ASCO) and Indian Cooperative Oncology Network (ICON).